 Home > Active Ingredient News > Drugs Articles > Ascent Pharma announces that it will announce six latest preclinical developments at the 2021 American Association for Cancer Research (AACR) Annual Meeting

Ascent Pharma announces that it will announce six latest preclinical developments at the 2021 American Association for Cancer Research (AACR) Annual Meeting

 Last Update: 2021-03-22
 Source: Internet
 Author: User

Tags

sacubitril drug class

hiv resistance mutation

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

us" style="margin:10px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">79);flex:100 100 0%;align-self:flex-start;height:auto;">us" style="margin:10px 0px 20px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">6;letter-spacing:1px;">

Ascent Pharmaceuticals (6855.
HK) announced that the company's six latest preclinical developments involving five original innovative drugs will be selected for the 2021 American Association for Cancer Research (AACR) annual meeting.
The abstract content has been announced on the AACR official website.
The AACR annual meeting will be held in the form of virtual meetings from April 10th to 15th and May 17th to 21st, Eastern Time.

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">79);flex:100 100 0%;align-self:flex-start;height:auto;">us" style="margin:10px 0px 20px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">6;letter-spacing:1px;">

79);flex:100 100 0%;align-self:flex-start;height:auto;">us" style="margin:10px 0px 20px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">6;letter-spacing:1px;">

us" style="margin:10px 0px 20px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">6;letter-spacing:1px;">

6;letter-spacing:1px;">

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">

us" style="margin:10px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:center;">438px;height:auto;">438px;height:auto;">us" style="margin:0px;padding:0px 15px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;color:#7D7D7D;line-height:1.

6;letter-spacing:0px;">

The American Association for Cancer Research (AACR) Annual Conference is one of the oldest and largest tumor research academic conferences in the world.

The conference focuses on all aspects of high-quality tumor research and innovation.
It is the focus of global tumor research and will bring together the most cutting-edge research results in the field of oncology.

The American Association for Cancer Research (AACR) Annual Conference is one of the oldest and largest tumor research academic conferences in the world.
The conference focuses on all aspects of high-quality tumor research and innovation.
It is the focus of global tumor research and will bring together the most cutting-edge research results in the field of oncology.

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">

us" style="margin:8px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:right;">766px;vertical-align:top;border-style:none;border-width:0px;border-color:#3E3E3E;box-shadow:#000000 0px 0px 0px;background-position:0% 0%;background-repeat:repeat;background-size:auto;background-attachment:scroll;background-image:url("https://mmbiz.

qpic.
cn/mmbiz_png/ibvEOgaMo6UE2yeeK2qamSl2rbl6EDpMCZYyR4HDAdJuW9LHBXXU8zBZAeyaWY2O0jBiaKcoicTyicicRMgD2akWYYA/640?wx_fmt=png");'>us" style="margin:0px;padding:10px 10px 0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;display:inline-block;width:884.
766px;vertical-align:top;background-color:#FFFFFF;border-style:solid;border-width:1px;border-color:#3E3E3E;">us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">797px;height:auto;">us" style="margin:10px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:left;font-size:11px;">qpic.
cn/mmbiz_png/ibvEOgaMo6UE2yeeK2qamSl2rbl6EDpMCwcLkzy1ekmOiag48MwgfDpelfOAmlu4SvmHWe9d01lZibB8fXCs7zpXw/640?wx_fmt=png");overflow:hidden;'>us" style="margin:30px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">4em;color:rgba(255, 255, 255, 0);">

2em;padding:0px;max-width:100%;box-sizing:border-box;clear:none;min-height:1em;display:inline-block;width:1em;float:right;"> Enter title

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">4em;color:rgba(255, 255, 255, 0);">

2em;padding:0px;max-width:100%;box-sizing:border-box;clear:none;min-height:1em;display:inline-block;width:1em;float:right;"> Enter title

953px;height:auto;">us" style="margin:10px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:left;">4375px;">us" style="margin:20px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:0px;">

I am very pleased that many of the company's new drug projects have been selected for many consecutive AACR annual meetings.

The results of this AACR show are mainly focused on the company's many important varieties of transformation research that have entered the clinical development stage.
These studies help us better understand the mechanism of drug action, determine effective combination applications, and discover new indications, thereby further advancing the company's clinical development process.

us" style="margin:10px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">4375px;">us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:justify;">

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:left;justify-content:flex-start;">797px;height:auto;align-self:flex-end;">us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:center;font-size:13px;">

Dr.

Yifan Zhai

Chief Medical Officer of Yasheng Pharmaceutical

953px;height:auto;align-self:flex-end;">us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:center;transform:translate3d(15px, 0px, 0px);">766px;vertical-align:top;border-style:none;border-width:0px;border-color:#3E3E3E;box-shadow:#000000 0px 0px 0px;background-position:0% 0%;background-repeat:repeat;background-size:auto;background-attachment:scroll;background-image:url("https://mmbiz.

qpic.

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">4em;color:rgba(255, 255, 255, 0);">

2em;padding:0px;max-width:100%;box-sizing:border-box;clear:none;min-height:1em;display:inline-block;width:1em;float:right;"> Enter title

I am very pleased that many of the company's new drug projects have been selected for many consecutive AACR annual meetings.

Dr.

Yifan Zhai

Chief Medical Officer of Yasheng Pharmaceutical

953px;height:auto;align-self:flex-end;">us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:center;transform:translate3d(15px, 0px, 0px);">us" style="margin:0px;padding:10px 10px 0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;display:inline-block;width:884.
766px;vertical-align:top;background-color:#FFFFFF;border-style:solid;border-width:1px;border-color:#3E3E3E;">us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">797px;height:auto;">us" style="margin:10px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:left;font-size:11px;">qpic.
cn/mmbiz_png/ibvEOgaMo6UE2yeeK2qamSl2rbl6EDpMCwcLkzy1ekmOiag48MwgfDpelfOAmlu4SvmHWe9d01lZibB8fXCs7zpXw/640?wx_fmt=png");overflow:hidden;'>us" style="margin:30px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">4em;color:rgba(255, 255, 255, 0);">

2em;padding:0px;max-width:100%;box-sizing:border-box;clear:none;min-height:1em;display:inline-block;width:1em;float:right;"> Enter title

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">4em;color:rgba(255, 255, 255, 0);">

2em;padding:0px;max-width:100%;box-sizing:border-box;clear:none;min-height:1em;display:inline-block;width:1em;float:right;"> Enter title

I am very pleased that many of the company's new drug projects have been selected for many consecutive AACR annual meetings.

Dr.

Yifan Zhai

Chief Medical Officer of Yasheng Pharmaceutical

953px;height:auto;align-self:flex-end;">us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:center;transform:translate3d(15px, 0px, 0px);">us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">797px;height:auto;">us" style="margin:10px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:left;font-size:11px;">qpic.
cn/mmbiz_png/ibvEOgaMo6UE2yeeK2qamSl2rbl6EDpMCwcLkzy1ekmOiag48MwgfDpelfOAmlu4SvmHWe9d01lZibB8fXCs7zpXw/640?wx_fmt=png");overflow:hidden;'>us" style="margin:30px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">4em;color:rgba(255, 255, 255, 0);">

2em;padding:0px;max-width:100%;box-sizing:border-box;clear:none;min-height:1em;display:inline-block;width:1em;float:right;"> Enter title

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">4em;color:rgba(255, 255, 255, 0);">

2em;padding:0px;max-width:100%;box-sizing:border-box;clear:none;min-height:1em;display:inline-block;width:1em;float:right;"> Enter title

I am very pleased that many of the company's new drug projects have been selected for many consecutive AACR annual meetings.

us" style="margin:10px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">4375px;">797px;height:auto;">us" style="margin:10px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:left;font-size:11px;">qpic.
cn/mmbiz_png/ibvEOgaMo6UE2yeeK2qamSl2rbl6EDpMCwcLkzy1ekmOiag48MwgfDpelfOAmlu4SvmHWe9d01lZibB8fXCs7zpXw/640?wx_fmt=png");overflow:hidden;'>us" style="margin:30px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">4em;color:rgba(255, 255, 255, 0);">

2em;padding:0px;max-width:100%;box-sizing:border-box;clear:none;min-height:1em;display:inline-block;width:1em;float:right;"> Enter title

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">4em;color:rgba(255, 255, 255, 0);">

2em;padding:0px;max-width:100%;box-sizing:border-box;clear:none;min-height:1em;display:inline-block;width:1em;float:right;"> Enter title

us" style="margin:10px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:left;font-size:11px;">qpic.
cn/mmbiz_png/ibvEOgaMo6UE2yeeK2qamSl2rbl6EDpMCwcLkzy1ekmOiag48MwgfDpelfOAmlu4SvmHWe9d01lZibB8fXCs7zpXw/640?wx_fmt=png");overflow:hidden;'>qpic.
cn/mmbiz_png/ibvEOgaMo6UE2yeeK2qamSl2rbl6EDpMCwcLkzy1ekmOiag48MwgfDpelfOAmlu4SvmHWe9d01lZibB8fXCs7zpXw/640?wx_fmt=png");overflow:hidden;'>qpic.
cn/mmbiz_png/ibvEOgaMo6UE2yeeK2qamSl2rbl6EDpMCwcLkzy1ekmOiag48MwgfDpelfOAmlu4SvmHWe9d01lZibB8fXCs7zpXw/640?wx_fmt=png");overflow:hidden;'>us" style="margin:30px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">4em;color:rgba(255, 255, 255, 0);">

2em;padding:0px;max-width:100%;box-sizing:border-box;clear:none;min-height:1em;display:inline-block;width:1em;float:right;"> Enter title

4em;color:rgba(255, 255, 255, 0);">

2em;padding:0px;max-width:100%;box-sizing:border-box;clear:none;min-height:1em;display:inline-block;width:1em;float:right;"> Enter title

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">4em;color:rgba(255, 255, 255, 0);">

2em;padding:0px;max-width:100%;box-sizing:border-box;clear:none;min-height:1em;display:inline-block;width:1em;float:right;"> Enter title

4em;color:rgba(255, 255, 255, 0);">

2em;padding:0px;max-width:100%;box-sizing:border-box;clear:none;min-height:1em;display:inline-block;width:1em;float:right;"> Enter title

I am very pleased that many of the company's new drug projects have been selected for many consecutive AACR annual meetings.
The results of this AACR show are mainly focused on the company's many important varieties of transformation research that have entered the clinical development stage.
These studies help us better understand the mechanism of drug action, determine effective combination applications, and discover new indications, thereby further advancing the company's clinical development process.

us" style="margin:10px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">4375px;">us" style="margin:10px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:left;">4375px;">4375px;">us" style="margin:20px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:0px;">

8;letter-spacing:0px;">

us" style="margin:10px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">4375px;">4375px;">us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:justify;">

Dr.
Yifan Zhai

Chief Medical Officer of Yasheng Pharmaceutical

953px;height:auto;align-self:flex-end;">us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:center;transform:translate3d(15px, 0px, 0px);">797px;height:auto;align-self:flex-end;">us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:center;font-size:13px;">

Dr.
Yifan Zhai

Chief Medical Officer of Yasheng Pharmaceutical

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:center;font-size:13px;">

Dr.
Yifan Zhai

Chief Medical Officer of Yasheng Pharmaceutical

Dr.
Yifan Zhai

Chief Medical Officer of Yasheng Pharmaceutical

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">us" style="margin:6px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">9;letter-spacing:0px;overflow-wrap:break-word ;">

The six research results were selected for the AACR poster and displayed as follows:

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;justify-content:flex-start;">us" style="margin:6px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">9;letter-spacing:0px;overflow-wrap:break-word ;">

The six research results were selected for the AACR poster and displayed as follows:

us" style="margin:6px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">9;letter-spacing:0px;overflow-wrap:break-word ;">

The six research results were selected for the AACR poster and displayed as follows:

9;letter-spacing:0px;overflow-wrap:break-word ;">

The six research results were selected for the AACR poster and displayed as follows:

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;justify-content:flex-start;">us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;justify-content:flex-start;">us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:center;transform:translate3d(1px, 0px, 0px);">us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;display:inline-block;width:905px;vertical-align:top;box-shadow:#000000 0px 0px 0px;line-height:2;letter-spacing:0px;border-width:1px;border-radius:5px;border-style:solid;border-color:rgba(213, 178, 122, 0.
49);overflow:hidden;">us" style="margin:0px;padding:3px 0px 0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;display:inline-block;width:903px;vertical-align:top;line-height:1;letter-spacing:0px;border-width:0px;">us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:justify;">

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:justify;">

us" style="margin:4px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#0670B9;">

Synergistic effect of BCL-2 inhibitor APG-2575 and homoharringtonine (HHT) in inducing apoptosis and inhibiting tumor growth in preclinical models of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#4C4447;">

BCL-2 inhibitor APG-2575 and homoharringtonine (HHT) synergistically induces apoptosis and inhibits tumor growth in preclinical models of acute myeloid leukemia and myelodysplastic syndromes (AML/MDS)

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;transform:translate3d(-10px, 0px, 0px);">2, 1, 0, 0);border-style:solid;border-width:0px;border-color:#4C4447;background-color:#0670B9;">us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;color:#FFFFFF;overflow-wrap:break-word ;">

Abstract/Poster Number

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

981

Sub-venue category

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:0px;overflow-wrap:break-word ;">

8px;">Experimental and Molecular Therapeutics

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

Experimental and molecular therapies

Session title

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

Cell Death Pathways and Treatment

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

Apoptosis pathway and treatment

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:justify;">

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;display:inline-block;width:905px;vertical-align:top;box-shadow:#000000 0px 0px 0px;line-height:2;letter-spacing:0px;border-width:1px;border-radius:5px;border-style:solid;border-color:rgba(213, 178, 122, 0.
49);overflow:hidden;">us" style="margin:0px;padding:3px 0px 0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;display:inline-block;width:903px;vertical-align:top;line-height:1;letter-spacing:0px;border-width:0px;">us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:justify;">

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:justify;">

us" style="margin:4px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#0670B9;">

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#4C4447;">

Abstract/Poster Number

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

981

Sub-venue category

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:0px;overflow-wrap:break-word ;">

8px;">Experimental and Molecular Therapeutics

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

Experimental and molecular therapies

Session title

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

Cell Death Pathways and Treatment

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

Apoptosis pathway and treatment

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:justify;">

us" style="margin:4px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#0670B9;">

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#4C4447;">

Abstract/Poster Number

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

981

Sub-venue category

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:0px;overflow-wrap:break-word ;">

8px;">Experimental and Molecular Therapeutics

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

Experimental and molecular therapies

Session title

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

Cell Death Pathways and Treatment

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

Apoptosis pathway and treatment

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:justify;">

us" style="margin:0px;padding:3px 0px 0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;display:inline-block;width:903px;vertical-align:top;line-height:1;letter-spacing:0px;border-width:0px;">us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:justify;">

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:justify;">

us" style="margin:4px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#0670B9;">

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#4C4447;">

Abstract/Poster Number

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

981

Sub-venue category

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:0px;overflow-wrap:break-word ;">

8px;">Experimental and Molecular Therapeutics

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

Experimental and molecular therapies

Session title

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

Cell Death Pathways and Treatment

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

Apoptosis pathway and treatment

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:justify;">

us" style="margin:4px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#0670B9;">

5;letter-spacing:0px;color:#0670B9;">

The synergistic effect of BCL -2 inhibitor APG-2575 and homoharringtonine (HHT) in inducing apoptosis and inhibiting tumor growth in preclinical models of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) BCL -2 Inhibitors APG-2575 and Homoharringtonine (HHT) synergistically induce apoptosis and inhibit tumor growth in preclinical models of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#4C4447;">

5;letter-spacing:0px;color:#4C4447;">

Abstract/Poster Number

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;transform:translate3d(-10px, 0px, 0px);">2, 1, 0, 0);border-style:solid;border-width:0px;border-color:#4C4447;background-color:#0670B9;">us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;color:#FFFFFF;overflow-wrap:break-word ;">

Abstract/Poster Number

2, 1, 0, 0);border-style:solid;border-width:0px;border-color:#4C4447;background-color:#0670B9;">us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;color:#FFFFFF;overflow-wrap:break-word ;">

Abstract/Poster Number

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;color:#FFFFFF;overflow-wrap:break-word ;">

Abstract/Poster Number

Abstract/Poster Number us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

981

8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

981

Sub-venue category

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;color:#FFFFFF;overflow-wrap:break-word ;">

Sub-venue category

Sub-venue category us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:0px;overflow-wrap:break-word ;">

8px;">Experimental and Molecular Therapeutics

8;letter-spacing:0px;overflow-wrap:break-word ;">

8px;">Experimental and Molecular Therapeutics

8px;">Experimental and Molecular Therapeuticsus" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

Experimental and molecular therapies

5;letter-spacing:0px;color:#757575;">

Experimental and molecular therapies

Experimental and molecular therapiesus" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;transform:translate3d(-10px, 0px, 0px);">2, 1, 0, 0);border-style:solid;border-width:0px;border-color:#4C4447;background-color:#0670B9;">us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;color:#FFFFFF;overflow-wrap:break-word ;">

Session title

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;color:#FFFFFF;overflow-wrap:break-word ;">

Session title

Session title us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

Cell Death Pathways and Treatment

8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

Cell Death Pathways and Treatment

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

Apoptosis pathway and treatment

5;letter-spacing:0px;color:#757575;">

Apoptosis pathway and treatment

Apoptosis pathway and treatmentus" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:justify;">

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:center;transform:translate3d(1px, 0px, 0px);">us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;display:inline-block;width:905px;vertical-align:top;box-shadow:#000000 0px 0px 0px;line-height:2;letter-spacing:0px;border-width:1px;border-radius:5px;border-style:solid;border-color:rgba(213, 178, 122, 0.
49);overflow:hidden;">us" style="margin:0px;padding:3px 0px 0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;display:inline-block;width:903px;vertical-align:top;line-height:1;letter-spacing:0px;border-width:0px;">us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:justify;">

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:justify;">

us" style="margin:4px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#0670B9;">

BCL-2 inhibition (APG-2575) and CDK4/6 inhibition synergistically induce cycle arrest and apoptosis of ER⁺ breast cancer cells

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#4C4447;">

Inhibition of BCL-2 (by APG-2575) and CDK4/6 synergistically induces cell cycle arrest and apoptosis in ER⁺ breast cancer

Abstract/Poster Number

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

976

Sub-venue category

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:0px;overflow-wrap:break-word ;">

8px;">Experimental and Molecular Therapeutics

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

Experimental and molecular therapies

Session title

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

Cell Death Pathways and Treatment

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

Apoptosis pathway and treatment

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:justify;">

us" style="margin:4px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#0670B9;">

BCL-2 inhibition (APG-2575) and CDK4/6 inhibition synergistically induce cycle arrest and apoptosis of ER⁺ breast cancer cells

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#4C4447;">

Inhibition of BCL-2 (by APG-2575) and CDK4/6 synergistically induces cell cycle arrest and apoptosis in ER⁺ breast cancer

Abstract/Poster Number

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

976

Sub-venue category

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:0px;overflow-wrap:break-word ;">

8px;">Experimental and Molecular Therapeutics

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

Experimental and molecular therapies

Session title

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

Cell Death Pathways and Treatment

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

Apoptosis pathway and treatment

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:justify;">

us" style="margin:4px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#0670B9;">

BCL-2 inhibition (APG-2575) and CDK4/6 inhibition synergistically induce cycle arrest and apoptosis of ER⁺ breast cancer cells

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#4C4447;">

Inhibition of BCL-2 (by APG-2575) and CDK4/6 synergistically induces cell cycle arrest and apoptosis in ER⁺ breast cancer

Abstract/Poster Number

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

976

Sub-venue category

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:0px;overflow-wrap:break-word ;">

8px;">Experimental and Molecular Therapeutics

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

Experimental and molecular therapies

Session title

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

Cell Death Pathways and Treatment

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

Apoptosis pathway and treatment

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:justify;">

us" style="margin:4px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#0670B9;">

BCL-2 inhibition (APG-2575) and CDK4/6 inhibition synergistically induce cycle arrest and apoptosis of ER⁺ breast cancer cells

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#4C4447;">

Inhibition of BCL-2 (by APG-2575) and CDK4/6 synergistically induces cell cycle arrest and apoptosis in ER⁺ breast cancer

Abstract/Poster Number

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

976

Sub-venue category

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:0px;overflow-wrap:break-word ;">

8px;">Experimental and Molecular Therapeutics

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

Experimental and molecular therapies

Session title

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

Cell Death Pathways and Treatment

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

Apoptosis pathway and treatment

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:justify;">

us" style="margin:4px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#0670B9;">

BCL-2 inhibition (APG-2575) and CDK4/6 inhibition synergistically induce cycle arrest and apoptosis of ER⁺ breast cancer cells

5;letter-spacing:0px;color:#0670B9;">

BCL-2 inhibition (APG-2575) and CDK4/6 inhibition synergistically induce cycle arrest and apoptosis of ER⁺ breast cancer cells

BCL-2 inhibition (APG-2575) and CDK4/6 inhibition synergistically induce ER⁺ breast cancer cell cycle arrest and apoptosis BCL-2 inhibition (APG-2575) and CDK4/6 inhibition synergistically induce ER⁺ breast cancer cells Cycle arrest and apoptosisus" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#4C4447;">

Inhibition of BCL-2 (by APG-2575) and CDK4/6 synergistically induces cell cycle arrest and apoptosis in ER⁺ breast cancer

5;letter-spacing:0px;color:#4C4447;">

Inhibition of BCL-2 (by APG-2575) and CDK4/6 synergistically induces cell cycle arrest and apoptosis in ER⁺ breast cancer

Abstract/Poster Number

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;color:#FFFFFF;overflow-wrap:break-word ;">

Abstract/Poster Number

Abstract/Poster Number us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

976

8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

976

Sub-venue category

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;color:#FFFFFF;overflow-wrap:break-word ;">

Sub-venue category

Sub-venue category us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:0px;overflow-wrap:break-word ;">

8px;">Experimental and Molecular Therapeutics

8;letter-spacing:0px;overflow-wrap:break-word ;">

8px;">Experimental and Molecular Therapeutics

8px;">Experimental and Molecular Therapeuticsus" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

Experimental and molecular therapies

5;letter-spacing:0px;color:#757575;">

Experimental and molecular therapies

Session title

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;color:#FFFFFF;overflow-wrap:break-word ;">

Session title

Session title us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

Cell Death Pathways and Treatment

8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

Cell Death Pathways and Treatment

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

Apoptosis pathway and treatment

5;letter-spacing:0px;color:#757575;">

Apoptosis pathway and treatment

Apoptosis pathway and treatmentus" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:justify;">

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:justify;">

us" style="margin:4px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#0670B9;">

FMS-like tyrosine kinase 3 (FLT3) inhibitor auribatinib (HQP1351) down-regulates MCL-1 and BCL-2 inhibitor APG-2575 in a preclinical model of FLT3 mutant acute myeloid leukemia (AML) Synergy

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#4C4447;">

FMS-like tyrosine kinase 3 (FLT3) inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor APG-2575 in preclinical models of FLT3-mutant acute myeloid leukemia (AML)

Abstract/Poster Number

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

1096

Sub-venue category

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:0px;overflow-wrap:break-word ;">

8px;">Experimental and Molecular Therapeutics

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

Experimental and molecular therapies

Session title

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

Drug Resistance in Molecular Targeted Therapies

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

Drug resistance of molecular targeted therapy

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:justify;">

us" style="margin:4px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#0670B9;">

FMS-like tyrosine kinase 3 (FLT3) inhibitor auribatinib (HQP1351) down-regulates MCL-1 and BCL-2 inhibitor APG-2575 in a preclinical model of FLT3 mutant acute myeloid leukemia (AML) Synergy

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#4C4447;">

Abstract/Poster Number

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

1096

Sub-venue category

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:0px;overflow-wrap:break-word ;">

8px;">Experimental and Molecular Therapeutics

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

Experimental and molecular therapies

Session title

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

Drug Resistance in Molecular Targeted Therapies

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

Drug resistance of molecular targeted therapy

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:justify;">

us" style="margin:4px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#0670B9;">

FMS-like tyrosine kinase 3 (FLT3) inhibitor auribatinib (HQP1351) down-regulates MCL-1 and BCL-2 inhibitor APG-2575 in a preclinical model of FLT3 mutant acute myeloid leukemia (AML) Synergy

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#4C4447;">

Abstract/Poster Number

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

1096

Sub-venue category

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:0px;overflow-wrap:break-word ;">

8px;">Experimental and Molecular Therapeutics

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

Experimental and molecular therapies

Session title

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

Drug Resistance in Molecular Targeted Therapies

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

Drug resistance of molecular targeted therapy

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:justify;">

us" style="margin:4px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#0670B9;">

FMS-like tyrosine kinase 3 (FLT3) inhibitor auribatinib (HQP1351) down-regulates MCL-1 and BCL-2 inhibitor APG-2575 in a preclinical model of FLT3 mutant acute myeloid leukemia (AML) Synergy

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#4C4447;">

Abstract/Poster Number

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

1096

Sub-venue category

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:0px;overflow-wrap:break-word ;">

8px;">Experimental and Molecular Therapeutics

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

Experimental and molecular therapies

Session title

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

Drug Resistance in Molecular Targeted Therapies

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

Drug resistance of molecular targeted therapy

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:justify;">

us" style="margin:4px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#0670B9;">

FMS-like tyrosine kinase 3 (FLT3) inhibitor auribatinib (HQP1351) down-regulates MCL-1 and BCL-2 inhibitor APG-2575 in a preclinical model of FLT3 mutant acute myeloid leukemia (AML) Synergy

5;letter-spacing:0px;color:#0670B9;">

FMS-like tyrosine kinase 3 (FLT3) inhibitor auribatinib (HQP1351) down-regulates MCL-1 and BCL-2 inhibitor APG-2575 in a preclinical model of FLT3 mutant acute myeloid leukemia (AML) Synergy

FMS-like tyrosine kinase 3 (FLT3) inhibitor auribatinib (HQP1351) down-regulates MCL-1 and BCL-2 inhibitor APG-2575 in a preclinical model of FLT3 mutant acute myeloid leukemia (AML) The synergistic effect of FMS-like tyrosine kinase 3 (FLT3) inhibitor auribatinib (HQP1351) through down-regulation of MCL-1 and BCL-2 inhibitor APG-2575 in clinical FLT3 mutant acute myeloid leukemia (AML) Synergy in the former modelus" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#4C4447;">

5;letter-spacing:0px;color:#4C4447;">

Abstract/Poster Number

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;color:#FFFFFF;overflow-wrap:break-word ;">

Abstract/Poster Number

Abstract/Poster Number us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

1096

8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

1096

Sub-venue category

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;color:#FFFFFF;overflow-wrap:break-word ;">

Sub-venue category

Sub-venue category us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:0px;overflow-wrap:break-word ;">

8px;">Experimental and Molecular Therapeutics

8;letter-spacing:0px;overflow-wrap:break-word ;">

8px;">Experimental and Molecular Therapeutics

8px;">Experimental and Molecular Therapeuticsus" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

Experimental and molecular therapies

5;letter-spacing:0px;color:#757575;">

Experimental and molecular therapies

Session title

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;color:#FFFFFF;overflow-wrap:break-word ;">

Session title

Session title us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

Drug Resistance in Molecular Targeted Therapies

8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

Drug Resistance in Molecular Targeted Therapies

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

Drug resistance of molecular targeted therapy

5;letter-spacing:0px;color:#757575;">

Drug resistance of molecular targeted therapy

Drug resistance of molecular targeted therapyus" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:justify;">

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:justify;">

us" style="margin:4px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#0670B9;">

Study on the therapeutic potential of inhibitor of apoptosis protein (IAP) APG-1387 combined with DR5 agonist CTB-006 monoclonal antibody (mAb) in preclinical models of solid tumors

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#4C4447;">

Therapeutic potential of inhibitor of apoptosis protein (IAP) inhibitor APG-1387 combined with DR5 agonist monoclonal antibody (mAb) CTB-006 in preclinical models of solid tumors

Abstract/Poster Number

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

1924

Sub-venue category

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:0px;overflow-wrap:break-word ;">

8px;">Molecular and Cellular Biology / Genetics

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

Molecular and cell biology/genetics

Session title

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

Apoptosis

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:justify;">

us" style="margin:4px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#0670B9;">

(IAP)APG-1387DR5CTB-006(mAb)

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#4C4447;">

Therapeutic potential of inhibitor of apoptosis protein (IAP) inhibitor APG-1387 combined with DR5 agonist monoclonal antibody (mAb) CTB-006 in preclinical models of solid tumors

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

1924

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:0px;overflow-wrap:break-word ;">

8px;">Molecular and Cellular Biology / Genetics

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

Apoptosis

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:justify;">

us" style="margin:4px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#0670B9;">

(IAP)APG-1387DR5CTB-006(mAb)

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#4C4447;">

Therapeutic potential of inhibitor of apoptosis protein (IAP) inhibitor APG-1387 combined with DR5 agonist monoclonal antibody (mAb) CTB-006 in preclinical models of solid tumors

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

1924

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:0px;overflow-wrap:break-word ;">

8px;">Molecular and Cellular Biology / Genetics

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

Apoptosis

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:justify;">

us" style="margin:4px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#0670B9;">

(IAP)APG-1387DR5CTB-006(mAb)

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#4C4447;">

Therapeutic potential of inhibitor of apoptosis protein (IAP) inhibitor APG-1387 combined with DR5 agonist monoclonal antibody (mAb) CTB-006 in preclinical models of solid tumors

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

1924

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:0px;overflow-wrap:break-word ;">

8px;">Molecular and Cellular Biology / Genetics

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

Apoptosis

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:justify;">

us" style="margin:4px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#0670B9;">

(IAP)APG-1387DR5CTB-006(mAb)

5;letter-spacing:0px;color:#0670B9;">

(IAP)APG-1387DR5CTB-006(mAb)

(IAP)APG-1387DR5CTB-006(mAb)(IAP)APG-1387DR5CTB-006(mAb)us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#4C4447;">

Therapeutic potential of inhibitor of apoptosis protein (IAP) inhibitor APG-1387 combined with DR5 agonist monoclonal antibody (mAb) CTB-006 in preclinical models of solid tumors

5;letter-spacing:0px;color:#4C4447;">

Therapeutic potential of inhibitor of apoptosis protein (IAP) inhibitor APG-1387 combined with DR5 agonist monoclonal antibody (mAb) CTB-006 in preclinical models of solid tumors

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;color:#FFFFFF;overflow-wrap:break-word ;">

/ us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

1924

8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

1924

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;color:#FFFFFF;overflow-wrap:break-word ;">

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:0px;overflow-wrap:break-word ;">

8px;">Molecular and Cellular Biology / Genetics

8;letter-spacing:0px;overflow-wrap:break-word ;">

8px;">Molecular and Cellular Biology / Genetics

8px;">Molecular and Cellular Biology / Geneticsus" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

5;letter-spacing:0px;color:#757575;">

/us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;transform:translate3d(-10px, 0px, 0px);">2, 1, 0, 0);border-style:solid;border-width:0px;border-color:#4C4447;background-color:#0670B9;">us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;color:#FFFFFF;overflow-wrap:break-word ;">

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;color:#FFFFFF;overflow-wrap:break-word ;">

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

Apoptosis

8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

Apoptosis

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

5;letter-spacing:0px;color:#757575;">

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:justify;">

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:justify;">

us" style="margin:4px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#0670B9;">

APG-1252 (pelcitoclax) BCL-xL(NEN)

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#4C4447;">

Targeting BCL-xL addiction with APG-1252 (pelcitoclax) to overcome apoptotic blockade in neuroendocrine neoplasm (NEN)

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

984

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:0px;overflow-wrap:break-word ;">

8px;">Experimental and Molecular Therapeutics

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

Cell Death Pathways and Treatment

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:justify;">

us" style="margin:4px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#0670B9;">

APG-1252 (pelcitoclax) BCL-xL(NEN)

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#4C4447;">

Targeting BCL-xL addiction with APG-1252 (pelcitoclax) to overcome apoptotic blockade in neuroendocrine neoplasm (NEN)

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

984

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:0px;overflow-wrap:break-word ;">

8px;">Experimental and Molecular Therapeutics

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

Cell Death Pathways and Treatment

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:justify;">

us" style="margin:4px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#0670B9;">

APG-1252 (pelcitoclax) BCL-xL(NEN)

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#4C4447;">

Targeting BCL-xL addiction with APG-1252 (pelcitoclax) to overcome apoptotic blockade in neuroendocrine neoplasm (NEN)

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

984

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:0px;overflow-wrap:break-word ;">

8px;">Experimental and Molecular Therapeutics

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

Cell Death Pathways and Treatment

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:justify;">

us" style="margin:4px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#0670B9;">

APG-1252 (pelcitoclax) BCL-xL(NEN)

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#4C4447;">

Targeting BCL-xL addiction with APG-1252 (pelcitoclax) to overcome apoptotic blockade in neuroendocrine neoplasm (NEN)

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

984

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:0px;overflow-wrap:break-word ;">

8px;">Experimental and Molecular Therapeutics

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

Cell Death Pathways and Treatment

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:justify;">

us" style="margin:4px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#0670B9;">

APG-1252 (pelcitoclax) BCL-xL(NEN)

5;letter-spacing:0px;color:#0670B9;">

APG-1252 (pelcitoclax) BCL-xL(NEN)

APG-1252 (pelcitoclax) BCL-xL(NEN)APG-1252 (pelcitoclax) BCL-xL(NEN)us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#4C4447;">

Targeting BCL-xL addiction with APG-1252 (pelcitoclax) to overcome apoptotic blockade in neuroendocrine neoplasm (NEN)

5;letter-spacing:0px;color:#4C4447;">

Targeting BCL-xL addiction with APG-1252 (pelcitoclax) to overcome apoptotic blockade in neuroendocrine neoplasm (NEN)

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;color:#FFFFFF;overflow-wrap:break-word ;">

/ us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

984

8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

984

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;color:#FFFFFF;overflow-wrap:break-word ;">

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:0px;overflow-wrap:break-word ;">

8px;">Experimental and Molecular Therapeutics

8;letter-spacing:0px;overflow-wrap:break-word ;">

8px;">Experimental and Molecular Therapeutics

8px;">Experimental and Molecular Therapeuticsus" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

5;letter-spacing:0px;color:#757575;">

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;color:#FFFFFF;overflow-wrap:break-word ;">

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

Cell Death Pathways and Treatment

8;letter-spacing:1.
8px;overflow-wrap:break-word ;">

Cell Death Pathways and Treatment

us" style="margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">5;letter-spacing:0px;color:#757575;">

5;letter-spacing:0px;color:#757575;">

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:justify;">

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;text-align:center;transform:translate3d(1px, 0px, 0px);">us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;display:inline-block;width:905px;vertical-align:top;box-shadow:#000000 0px 0px 0px;line-height:2;letter-spacing:0px;border-width:1px;border-radius:5px;border-style:solid;border-color:rgba(213, 178, 122, 0.
49);overflow:hidden;">us" style="margin:0px;padding:3px 0px 0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;display:inline-block;width:903px;vertical-align:top;line-height:1;letter-spacing:0px;border-width:0px;">us" style='margin:0px;padding:0px;max-width:100%;box-sizing:border-box;color:#333333;font-family:-apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:14px;white-space:normal;background-color:#FFFFFF;text-align:justify;overflow-wrap:break-word ;'>

us" style='margin:4px 0px;padding:0px;max-width:100%;box-sizing:border-box;color:#333333;font-family:-apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:14px;white-space:normal;background-color:#FFFFFF;overflow-wrap:break-word ;'>5;letter-spacing:0px;color:#0670B9;">

(FAK)APG-2449CD44

us" style='margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;color:#333333;font-family:-apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:14px;white-space:normal;background-color:#FFFFFF;overflow-wrap:break-word ;'>5;letter-spacing:0px;color:#4C4447;">

Focal adhesion kinase (FAK) inhibitor APG-2449 sensitizes ovarian tumors to chemotherapy via CD44 downregulation

968

8px;">Experimental and Molecular Therapeutics

Biological Therapeutic Agents

us" style='margin:0px;padding:0px;max-width:100%;box-sizing:border-box;color:#333333;font-family:-apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:14px;white-space:normal;background-color:#FFFFFF;text-align:justify;overflow-wrap:break-word ;'>us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;display:inline-block;width:905px;vertical-align:top;box-shadow:#000000 0px 0px 0px;line-height:2;letter-spacing:0px;border-width:1px;border-radius:5px;border-style:solid;border-color:rgba(213, 178, 122, 0.
49);overflow:hidden;">us" style="margin:0px;padding:3px 0px 0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;display:inline-block;width:903px;vertical-align:top;line-height:1;letter-spacing:0px;border-width:0px;">us" style='margin:0px;padding:0px;max-width:100%;box-sizing:border-box;color:#333333;font-family:-apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:14px;white-space:normal;background-color:#FFFFFF;text-align:justify;overflow-wrap:break-word ;'>

(FAK)APG-2449CD44

Focal adhesion kinase (FAK) inhibitor APG-2449 sensitizes ovarian tumors to chemotherapy via CD44 downregulation

968

8px;">Experimental and Molecular Therapeutics

Biological Therapeutic Agents

(FAK)APG-2449CD44

Focal adhesion kinase (FAK) inhibitor APG-2449 sensitizes ovarian tumors to chemotherapy via CD44 downregulation

968

8px;">Experimental and Molecular Therapeutics

Biological Therapeutic Agents

us" style='margin:0px;padding:0px;max-width:100%;box-sizing:border-box;color:#333333;font-family:-apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:14px;white-space:normal;background-color:#FFFFFF;text-align:justify;overflow-wrap:break-word ;'>us" style="margin:0px;padding:3px 0px 0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;display:inline-block;width:903px;vertical-align:top;line-height:1;letter-spacing:0px;border-width:0px;">us" style='margin:0px;padding:0px;max-width:100%;box-sizing:border-box;color:#333333;font-family:-apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:14px;white-space:normal;background-color:#FFFFFF;text-align:justify;overflow-wrap:break-word ;'>

(FAK)APG-2449CD44

Focal adhesion kinase (FAK) inhibitor APG-2449 sensitizes ovarian tumors to chemotherapy via CD44 downregulation

968

8px;">Experimental and Molecular Therapeutics

Biological Therapeutic Agents

(FAK)APG-2449CD44

5;letter-spacing:0px;color:#0670B9;">

(FAK)APG-2449CD44

(FAK)APG-2449CD44(FAK)APG-2449CD44us" style='margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;color:#333333;font-family:-apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:14px;white-space:normal;background-color:#FFFFFF;overflow-wrap:break-word ;'>5;letter-spacing:0px;color:#4C4447;">

Focal adhesion kinase (FAK) inhibitor APG-2449 sensitizes ovarian tumors to chemotherapy via CD44 downregulation

5;letter-spacing:0px;color:#4C4447;">

Focal adhesion kinase (FAK) inhibitor APG-2449 sensitizes ovarian tumors to chemotherapy via CD44 downregulation

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;font-size:12px;color:#FFFFFF;">

/ us" style='margin:0px;padding:0px;max-width:100%;box-sizing:border-box;color:#333333;font-family:-apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:14px;white-space:normal;background-color:#FFFFFF;overflow-wrap:break-word ;'>8;letter-spacing:1.
8px;">

968

8;letter-spacing:1.
8px;">

968

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;font-size:12px;color:#FFFFFF;">

8px;">Experimental and Molecular Therapeutics

8;letter-spacing:0px;">

8px;">Experimental and Molecular Therapeutics

8px;">Experimental and Molecular Therapeuticsus" style='margin:3px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box;color:#333333;font-family:-apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:14px;white-space:normal;background-color:#FFFFFF;overflow-wrap:break-word ;'>5;letter-spacing:0px;color:#757575;">

5;letter-spacing:0px;color:#757575;">

us" style="margin:0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;font-size:12px;color:#FFFFFF;">

Biological Therapeutic Agents

8;letter-spacing:1.
8px;">

Biological Therapeutic Agents

5;letter-spacing:0px;color:#757575;">

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.